IL114996A - 1-biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same - Google Patents
1-biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the sameInfo
- Publication number
- IL114996A IL114996A IL114996A IL11499692A IL114996A IL 114996 A IL114996 A IL 114996A IL 114996 A IL114996 A IL 114996A IL 11499692 A IL11499692 A IL 11499692A IL 114996 A IL114996 A IL 114996A
- Authority
- IL
- Israel
- Prior art keywords
- group
- carbon atoms
- groups
- hydrogen atom
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 46
- 125000000217 alkyl group Chemical group 0.000 abstract 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 15
- 125000003545 alkoxy group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000002252 acyl group Chemical group 0.000 abstract 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 5
- -1 pivaloyloxymethyl group Chemical group 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000005156 substituted alkylene group Chemical group 0.000 abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 abstract 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 abstract 2
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000007717 exclusion Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000005633 phthalidyl group Chemical group 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Phenolic Resins Or Amino Resins (AREA)
- Dental Preparations (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2709891 | 1991-02-21 | ||
JP9658891 | 1991-04-26 | ||
JP13488991 | 1991-06-06 | ||
JP16713891 | 1991-07-08 | ||
JP17397291 | 1991-07-15 | ||
JP18484191 | 1991-07-24 | ||
IL10103495 | 1995-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL114996A true IL114996A (en) | 1997-07-13 |
Family
ID=27549327
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10103492A IL101034A (en) | 1991-02-21 | 1992-02-21 | History of 1-biphenylimidazole, processes for their preparation, and pharmaceutical preparations containing them |
IL114996A IL114996A (en) | 1991-02-21 | 1992-02-21 | 1-biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same |
IL11499695A IL114996A0 (en) | 1991-02-21 | 1995-08-18 | 1-Biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10103492A IL101034A (en) | 1991-02-21 | 1992-02-21 | History of 1-biphenylimidazole, processes for their preparation, and pharmaceutical preparations containing them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11499695A IL114996A0 (en) | 1991-02-21 | 1995-08-18 | 1-Biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP0545912B1 (fr) |
JP (1) | JPH07121918B2 (fr) |
KR (1) | KR0128289B1 (fr) |
CN (3) | CN1045770C (fr) |
AT (2) | ATE200778T1 (fr) |
CA (2) | CA2061607C (fr) |
CZ (1) | CZ289194B6 (fr) |
DE (6) | DE10299043I2 (fr) |
DK (2) | DK0503785T3 (fr) |
ES (2) | ES2157895T7 (fr) |
FI (2) | FI112942B3 (fr) |
GR (2) | GR3035906T3 (fr) |
HK (2) | HK1011361A1 (fr) |
HU (3) | HU223338B1 (fr) |
IE (1) | IE920540A1 (fr) |
IL (3) | IL101034A (fr) |
IS (1) | IS1756B (fr) |
LU (4) | LU91056I2 (fr) |
NL (3) | NL300133I2 (fr) |
NO (6) | NO304516B3 (fr) |
NZ (1) | NZ241681A (fr) |
PT (2) | PT503785E (fr) |
RU (1) | RU2128173C1 (fr) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
DE69329982T2 (de) * | 1992-06-02 | 2001-09-27 | Sankyo Co | 4-Carboxyimidazolderivate als Angiotensin-II-Antagonisten und ihre therapeutische Verwendung |
NO304429B1 (no) * | 1992-12-17 | 1998-12-14 | Sankyo Co | Bifenylderivater, farmas°ytisk preparat og deres anvendelse for fremstilling av et medikament for behandling av hypertensjon og hjertesykdom |
US5395844A (en) * | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
KR100211446B1 (ko) * | 1994-03-16 | 1999-08-02 | 가와무라 요시부미 | 안압 저하제 |
TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
AUPN786896A0 (en) | 1996-02-02 | 1996-02-29 | Telstra Corporation Limited | A network fault system |
WO1998002183A1 (fr) * | 1996-07-15 | 1998-01-22 | Sankyo Company, Limited | Compositions medicinales |
AU5576498A (en) * | 1997-02-05 | 1998-08-26 | Sankyo Company Limited | Prophylactic or therapeutic agent for diabetic complication |
EP1193258A4 (fr) | 1999-06-22 | 2002-11-13 | Takeda Chemical Industries Ltd | Methode de preparation de derives d'imidazole |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
JP4521844B2 (ja) * | 2000-04-18 | 2010-08-11 | 日本曹達株式会社 | 4,5−ジシアノイミダゾールの製造方法 |
EP1314425A4 (fr) * | 2000-08-30 | 2004-06-02 | Sankyo Co | Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
EP1595540A1 (fr) | 2000-11-21 | 2005-11-16 | Sankyo Company Limited | Composition comprenant un antagoniste du recepteur de l'angiotensine II et un diuretique et leur utilisation pour le traitement de l'hypertension |
EP1421953A4 (fr) * | 2001-08-28 | 2004-09-15 | Sankyo Co | Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii |
AU2004208615C1 (en) | 2003-01-31 | 2010-05-13 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
CN1197866C (zh) * | 2003-03-21 | 2005-04-20 | 上海医药工业研究院 | 4,6-二氢呋喃并[3,4-d]咪唑-6-酮衍生物及其盐和制备方法 |
ES2535291T3 (es) | 2003-04-15 | 2015-05-08 | Daiichi Sankyo Company, Limited | Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
GB0316546D0 (en) | 2003-07-15 | 2003-08-20 | Novartis Ag | Process for the manufacture of organic compounds |
US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
JP2005206603A (ja) * | 2004-01-21 | 2005-08-04 | Teva Pharmaceutical Industries Ltd | カンデサルタンシレキセチルの調製 |
GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
CA2555294A1 (fr) | 2004-02-11 | 2005-08-25 | Marina Yu Etinger | Polymorphes de candesartan cilexetil |
US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
BRPI0508880A (pt) | 2004-03-17 | 2007-09-04 | Novartis Ag | uso de compostos orgánicos |
WO2006029056A1 (fr) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Preparation d'olmesartan medoxomil |
CA2580862A1 (fr) | 2004-10-08 | 2006-04-20 | Novartis Ag | Utilisation d'inhibiteurs de renine pour la prevention ou le traitement du dysfonctionnement diastolique ou de la cardiopathie diastolique |
NZ555325A (en) | 2004-10-27 | 2009-07-31 | Daiichi Sankyo Co Ltd | Benzene compound having 2 or more substituents |
JP2007525504A (ja) * | 2004-12-30 | 2007-09-06 | テバ ファーマシューティカル インダストリーズ リミティド | 2.5よりも高いpHでオルメサルタンメドキソミルを調製するための方法 |
CA2592160A1 (fr) * | 2005-01-03 | 2006-07-13 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil a teneur reduite en impuretes |
JP5051897B2 (ja) * | 2005-04-22 | 2012-10-17 | 第一三共株式会社 | 骨代謝性疾患の予防又は治療のための医薬 |
EP1910343B1 (fr) * | 2005-07-29 | 2014-10-29 | Krka | Procédé de préparation d'olmesartane medoxomil |
EP1816131A1 (fr) * | 2006-02-06 | 2007-08-08 | KRKA, tovarna zdravil, d.d., Novo mesto | Procédé pour la préparation du olmesartan medoxomil |
CZ299265B6 (cs) * | 2005-10-20 | 2008-05-28 | Zentiva, A. S. | Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu) |
CZ299902B6 (cs) * | 2005-10-27 | 2008-12-29 | Zentiva, A. S | Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv |
EP1801111B1 (fr) * | 2005-12-20 | 2014-07-16 | LEK Pharmaceuticals d.d. | Formes polymorphes du Olmesartan Medoxomil |
CA2642988C (fr) * | 2006-02-27 | 2015-10-27 | Takeda Pharmaceutical Company Limited | Produit pharmaceutique contenant un benzimidazole en combinaison avec undessechant |
EP1891952B1 (fr) | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Composition pharmaceutique d'olmésartan médoxomil |
US8048904B2 (en) * | 2006-06-19 | 2011-11-01 | Matrix Laboratories Ltd. | Process for the preparation of olmesartan medoxomil |
KR101126383B1 (ko) | 2007-02-07 | 2012-04-12 | 교와 핫꼬 기린 가부시키가이샤 | 3환계 화합물 |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
CA2681591A1 (fr) * | 2007-03-23 | 2008-10-02 | Daiichi Sankyo Company, Limited | Cristal moulu d'olmesartan medoxomil |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
TWI448284B (zh) * | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
CN101311169B (zh) * | 2007-05-21 | 2011-03-16 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法 |
CN101311168B (zh) * | 2007-05-21 | 2010-12-08 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2008151257A2 (fr) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
GB0710680D0 (en) * | 2007-06-05 | 2007-07-11 | Generics Uk Ltd | Novel crystalline form of olmesartan medoxmil |
WO2009001661A1 (fr) * | 2007-06-22 | 2008-12-31 | Daiichi Sankyo Company, Limited | Agent médicamenteux pour la prévention ou le traitement de la maladie d'alzheimer |
EP2328910B1 (fr) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
US8735598B2 (en) | 2008-06-09 | 2014-05-27 | Daiichi Sankyo Company, Limited | Method for producing 1-biphenylmethylimidazole compound |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US8486980B2 (en) | 2008-08-06 | 2013-07-16 | Kyowa Hakko Kirin Co., Ltd. | Tricyclic compound |
JP5395908B2 (ja) | 2008-11-17 | 2014-01-22 | 浙江海正薬業股▲ふん▼有限公司 | 4−(1−ヒドロキシ−1−メチルエチル)−2−プロピルイミダゾール−5−カルボン酸エステルの製造方法 |
JP2009102340A (ja) * | 2008-12-04 | 2009-05-14 | Daiichi Sankyo Co Ltd | イミダゾール誘導体の製造法(2) |
US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
BRPI1013336B1 (pt) | 2009-04-28 | 2020-02-04 | Daiichi Sankyo Co Ltd | cristais solvatos de acetona, métodos para produção dos referidos cristais e método para produção de olmesartana medoxomila |
WO2010126013A1 (fr) | 2009-04-28 | 2010-11-04 | 第一三共株式会社 | Procédé de production de l'olmésartan médoxomil |
PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
CN102050816A (zh) * | 2009-10-28 | 2011-05-11 | 北京万全阳光医学技术有限公司 | 一种合成奥美沙坦酯的方法 |
HUP0900788A2 (en) | 2009-12-16 | 2011-11-28 | Sanofi Aventis | Process for producing 4-bromomethyl-biphenyl derivatives |
CA2785920A1 (fr) | 2010-01-05 | 2011-07-14 | Ratiopharm Gmbh | Forme posologique orale solide contenant de l'olmesartan medoxomil |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (fr) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Nouveaux inhibiteurs |
JP5137996B2 (ja) * | 2010-04-28 | 2013-02-06 | 日本曹達株式会社 | 4,5−ジシアノイミダゾールの製造方法 |
IT1400311B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
EP2425859A1 (fr) | 2010-08-08 | 2012-03-07 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Formulations de l'olmesartane |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN102060778B (zh) * | 2010-12-24 | 2012-05-23 | 江苏江神药物化学有限公司 | 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法 |
CN102206208A (zh) * | 2010-12-24 | 2011-10-05 | 上海现代制药股份有限公司 | 含低水平杂质的奥美沙坦酯的制备方法 |
EP2686313B1 (fr) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase |
WO2013018899A1 (fr) | 2011-08-03 | 2013-02-07 | 協和発酵キリン株式会社 | Dérivé de dibenzooxépine |
BR112014014527A2 (pt) | 2011-12-15 | 2017-06-13 | Takeda Pharmaceuticals Usa Inc | combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros |
CN103304550B (zh) * | 2012-03-16 | 2016-01-27 | 湖南欧亚生物有限公司 | 一种奥美沙坦酯的制备方法 |
WO2014034868A1 (fr) | 2012-08-31 | 2014-03-06 | 株式会社エーピーアイ コーポレーション | Procédé de production d'un composé biaryle |
CN104662008B (zh) | 2012-09-26 | 2017-03-08 | 株式会社Api | 四唑化合物的脱保护方法 |
EP2905029B1 (fr) | 2012-10-04 | 2018-11-21 | Shionogi&Co., Ltd. | Médicament destiné à inhiber une métastase de tumeur maligne |
CN103012382B (zh) * | 2012-12-05 | 2016-10-05 | 迪沙药业集团有限公司 | 一种奥美沙坦酯的制备方法 |
CN103044407A (zh) * | 2012-12-20 | 2013-04-17 | 安徽悦康凯悦制药有限公司 | 奥美沙坦酯的制备方法 |
CN103965167A (zh) * | 2013-01-29 | 2014-08-06 | 通化济达医药有限公司 | 咪唑羧酸衍生物 |
JP2014152127A (ja) * | 2013-02-06 | 2014-08-25 | Tokuyama Corp | オルメサルタンメドキソミルの製造方法 |
CA2905438A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
EP2968439A2 (fr) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
EP3025711B1 (fr) | 2013-07-23 | 2020-11-18 | Daiichi Sankyo Company, Limited | Médicament destiné à la prévention ou au traitement de l'hypertension artérielle |
CN103880825B (zh) * | 2014-03-14 | 2019-03-05 | 浙江华海药业股份有限公司 | 一种高纯的三苯甲基奥美沙坦酯的制备工艺 |
CN104356069B (zh) * | 2014-11-18 | 2016-09-14 | 黄冈鲁班药业有限公司 | 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用 |
CN104447564B (zh) * | 2014-11-24 | 2016-08-31 | 广州天赐高新材料股份有限公司 | 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法 |
CN104402873A (zh) * | 2014-12-02 | 2015-03-11 | 千辉药业(安徽)有限责任公司 | 一种奥美沙坦酯中间体的制备方法 |
CN105481842A (zh) * | 2015-12-15 | 2016-04-13 | 江苏中邦制药有限公司 | 一种奥美沙坦酯的制备方法 |
KR20180123021A (ko) | 2016-03-24 | 2018-11-14 | 다이이찌 산쿄 가부시키가이샤 | 신질환의 치료를 위한 의약 |
CN106749195A (zh) * | 2016-12-30 | 2017-05-31 | 青岛黄海制药有限责任公司 | 一种奥美沙坦酯中间体杂质合成、鉴定的方法 |
CN107474042A (zh) * | 2017-09-07 | 2017-12-15 | 浙江华海致诚药业有限公司 | 一种三苯甲基奥美沙坦酯的晶型h |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
CN109081812B (zh) * | 2018-08-30 | 2022-08-16 | 黄冈鲁班药业股份有限公司 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物 |
KR102131359B1 (ko) | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
CN112778209B (zh) * | 2019-11-04 | 2024-05-14 | 宜昌东阳光长江药业股份有限公司 | 一种二酸的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
JPS5671073A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
IE802177L (en) | 1980-10-21 | 1981-05-12 | Takeda Chemical Industries Ltd | Imidazol-5-ylacetic acid derivatives |
US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
CA1334092C (fr) | 1986-07-11 | 1995-01-24 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii |
CA1338238C (fr) | 1988-01-07 | 1996-04-09 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens |
US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
US4916129A (en) | 1989-01-19 | 1990-04-10 | E. I. Du Pont De Nemours And Company | Combination β-blocking/angiotensin II blocking antihypertensives |
CA2016710A1 (fr) | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Benzimidazoles substitues comme antagonistes de l'antiotensine ii |
GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
IE64514B1 (en) | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
JPH05504359A (ja) | 1990-02-13 | 1993-07-08 | メルク・エンド・カムパニー・インコーポレーテツド | 置換ベンジル部分を含むイミダゾールアンギオテンシン2拮抗物質 |
US5140037A (en) | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
-
1992
- 1992-02-20 IE IE054092A patent/IE920540A1/en active Protection Beyond IP Right Term
- 1992-02-20 IS IS3819A patent/IS1756B/is unknown
- 1992-02-20 CA CA002061607A patent/CA2061607C/fr not_active Expired - Lifetime
- 1992-02-20 FI FI920749A patent/FI112942B3/fi not_active IP Right Cessation
- 1992-02-20 CA CA002229000A patent/CA2229000C/fr not_active Expired - Lifetime
- 1992-02-21 DE DE2002199043 patent/DE10299043I2/de active Active
- 1992-02-21 DE DE69231798T patent/DE69231798T3/de not_active Expired - Lifetime
- 1992-02-21 PT PT92301449T patent/PT503785E/pt unknown
- 1992-02-21 DE DE122009000024C patent/DE122009000024I1/de active Pending
- 1992-02-21 CN CN92102075A patent/CN1045770C/zh not_active Expired - Lifetime
- 1992-02-21 AT AT93200195T patent/ATE200778T1/de active
- 1992-02-21 EP EP93200195A patent/EP0545912B1/fr not_active Expired - Lifetime
- 1992-02-21 RU RU95101430A patent/RU2128173C1/ru active
- 1992-02-21 DK DK92301449T patent/DK0503785T3/da active
- 1992-02-21 IL IL10103492A patent/IL101034A/en not_active IP Right Cessation
- 1992-02-21 CZ CS1992516A patent/CZ289194B6/cs not_active IP Right Cessation
- 1992-02-21 DE DE200512000051 patent/DE122005000051I1/de active Pending
- 1992-02-21 PT PT93200195T patent/PT545912E/pt unknown
- 1992-02-21 NO NO19920688A patent/NO304516B3/no not_active IP Right Cessation
- 1992-02-21 EP EP92301449A patent/EP0503785B3/fr not_active Expired - Lifetime
- 1992-02-21 AT AT92301449T patent/ATE200777T1/de active
- 1992-02-21 DE DE69231801T patent/DE69231801T2/de not_active Expired - Lifetime
- 1992-02-21 ES ES92301449T patent/ES2157895T7/es active Active
- 1992-02-21 NZ NZ241681A patent/NZ241681A/en not_active IP Right Cessation
- 1992-02-21 HU HU9200578A patent/HU223338B1/hu active Protection Beyond IP Right Term
- 1992-02-21 IL IL114996A patent/IL114996A/xx not_active IP Right Cessation
- 1992-02-21 DE DE122011000011C patent/DE122011000011I1/de active Pending
- 1992-02-21 DK DK93200195T patent/DK0545912T3/da active
- 1992-02-21 ES ES93200195T patent/ES2156866T3/es not_active Expired - Lifetime
- 1992-02-21 JP JP4034970A patent/JPH07121918B2/ja not_active Expired - Lifetime
- 1992-02-21 KR KR1019920002676A patent/KR0128289B1/ko not_active IP Right Cessation
-
1994
- 1994-10-28 HU HU9601179A patent/HU223667B1/hu active IP Right Grant
-
1995
- 1995-06-29 HU HU95P/P00605P patent/HU211934A9/hu unknown
- 1995-08-18 IL IL11499695A patent/IL114996A0/xx unknown
- 1995-11-02 FI FI955248A patent/FI112941B/fi not_active IP Right Cessation
- 1995-11-09 NO NO954507A patent/NO304517B1/no not_active IP Right Cessation
-
1997
- 1997-12-24 CN CN97126347A patent/CN1121859C/zh not_active Expired - Lifetime
- 1997-12-24 CN CN97123452A patent/CN1101384C/zh not_active Expired - Lifetime
-
1998
- 1998-11-26 HK HK98112355A patent/HK1011361A1/xx not_active IP Right Cessation
- 1998-12-09 HK HK98113006A patent/HK1011969A1/xx not_active IP Right Cessation
-
2001
- 2001-05-22 GR GR20010400760T patent/GR3035906T3/el unknown
- 2001-05-22 GR GR20010400763T patent/GR3035909T3/el unknown
-
2003
- 2003-08-01 NL NL300133C patent/NL300133I2/nl unknown
- 2003-11-27 NO NO2003009C patent/NO2003009I2/no unknown
-
2004
- 2004-01-26 LU LU91056C patent/LU91056I2/fr unknown
-
2006
- 2006-03-30 NL NL300227C patent/NL300227I1/nl unknown
- 2006-10-09 NO NO2006012C patent/NO2006012I1/no unknown
-
2007
- 2007-04-02 LU LU91330C patent/LU91330I2/fr unknown
-
2009
- 2009-02-13 NL NL300375C patent/NL300375I1/nl unknown
- 2009-05-11 LU LU91571C patent/LU91571I2/fr unknown
- 2009-09-11 NO NO2009019C patent/NO2009019I1/no unknown
-
2011
- 2011-07-26 LU LU91847C patent/LU91847I2/fr unknown
- 2011-08-10 NO NO2011013C patent/NO2011013I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL114996A (en) | 1-biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | |
MX9203165A (es) | Derivados de succinimida y composicion farmaceutica que los contiene . | |
EP0860428A3 (fr) | Dérivés de sulfonamide | |
AR011093A1 (es) | Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso. | |
IE782493L (en) | Phosphonoformic acid derivatives | |
HUP9802865A2 (hu) | N-(szubsztituált fenil-)-pirazol-származékok, előállításuk és alkalmazásuk, a vegyületeket hatóanyagként tartalmazó parazitaellenes készítmények | |
EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
RS49850B (sr) | Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena | |
NZ332960A (en) | tetrahydro-cyclopropan[c]benz[e]-indol-4-one and tetrahydro-cyclopropan[c]benzo[e]-indole derivatives and medicaments | |
AU689304B2 (en) | Quinazoline derivative | |
ES538418A0 (es) | Un derivado de indol-3-carboxamida | |
AU591390B2 (en) | Arylcyclobutylalkyl amines and their use as antidepressive medicines | |
MXPA02001473A (es) | Azaindoles que tienen afinidad con el receptor de serotonina. | |
ATE61347T1 (de) | Zytoprotektive derivate zur anwendung bei ischaemischen erkrankungen, ihre herstellung und sie enthaltende zusammensetzungen. | |
HUP0000321A2 (hu) | NOS inhibitor hatású aromás aminszármazékok, eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
WO2002000638A3 (fr) | Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant | |
IL103019A0 (en) | Dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them | |
EP0335979A4 (en) | Thienopyrimidine derivatives | |
CO5150186A1 (es) | Derivados de 3-bencil-ureido y 2-guanidino-tiazol y preparaciones farmaceuticas que los contienen | |
NO20053302D0 (no) | Imidazolderivater med affinitet for alfa 2-reseptoraktivitet. | |
AR012249A1 (es) | Compuestos de amonio cuaternario, procedimiento para su preparacion, composicion farmaceutica que los contiene, y su uso para la preparacion de medicamentos | |
ATE9584T1 (de) | Antibakterielle beta-lactam-verbindungen, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
EP0016411A3 (en) | 5(10- 9)abeo-ergoline derivatives, their preparation, and therapeutic compositions containing them | |
DE3373302D1 (en) | Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them | |
ES8206525A1 (es) | Procedimiento para la preparacion de nuevas pirazinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |